Biocon/Fujifilm Enter Lantus Biosimilar Fray In Japan
This article was originally published in PharmAsia News
Executive Summary
Biocon and Fujifilm Pharma have received approval for their biosimilar insulin glargine from Japan's Ministry of Health, Labour and Welfare, marking what the Indian firm termed a "huge credibility milestone" and adding further pressure on innovator Sanofi's Lantus.
You may also be interested in...
GC Pharma/Biocon Eye Low Price Strategy As Biosimilar Insulin Glargine Approved In Korea
GC Pharma/Biocon are set to adopt a low price strategy for their biosimilar insulin glargine, which has just received regulatory approval in South Korea, to better compete with rival products.
GC Pharma/Biocon Eye Low Price Strategy As Biosimilar Insulin Glargine Approved In Korea
GC Pharma/Biocon are set to adopt a low price strategy for their biosimilar insulin glargine, which has just received regulatory approval in South Korea, to better compete with rival products.
Weak Q3 For Biocon, All Eyes On Biosimilars Approval Flow
Biocon reported a decline in profits for the third quarter but recent regulatory wins and advancements for its biosimilars portfolio could potentially bring an uptick in growth going forward.